Advanced Solid Tumor Clinical Trials in Huntersville, North Carolina

6 studies are recruiting for advanced solid tumor in Huntersville, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina Biooncology Institute, Huntersville, North Carolina

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina Biooncology Institute, Huntersville, North Carolina

   Locations

   13 in total

   Run by

   GI Innovation, Inc.

   See if you can join NCT04977453 on ClinicalTrials.gov

3. Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

   This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, LLC, Huntersville, North Carolina

   Locations

   11 in total

   Run by

   BioNTech SE

   See if you can join NCT06750185 on ClinicalTrials.gov

4. A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

   This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The inves…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Clinical Trial Site, Huntersville, North Carolina

   Locations

   3 in total

   Run by

   Arvinas Inc.

   See if you can join NCT07749586 on ClinicalTrials.gov

5. A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

   This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Locations

   8 in total

   Run by

   Peel Therapeutics Inc

   See if you can join NCT05329103 on ClinicalTrials.gov

6. A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

   The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology, Huntersville, North Carolina

   Locations

   8 in total

   Run by

   FBD Biologics Limited

   See if you can join NCT05892718 on ClinicalTrials.gov